Keywords: genentech, 3rd-qtr, income, climbs, sales, 9b, analysts

Genentech's 3rd-qtr income climbs 21% with sales of $2.9B; but analysts question reliance on Avastin

Article | 22 October 2007

Print This

\USA-based biotechnology firm Genentech, which is majority owned by Swiss drug major Roche, says that its net profit for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in